Oncology & Cancer

Bortezomib beneficial in graft-versus-host disease prophylaxis

(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from a prophylactic, ...

Immunology

Study reframes understanding of graft-versus-host disease

New research challenges the prevailing hypothesis for how donor stem cell grafts cause graft-versus-host disease, or GVHD, and offers an alternative model that could guide development of novel therapies.

Medical research

Safety switch preserves beneficial effects of cell therapy

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe ...

page 4 from 5